Tempus Next supports providers in closing gaps in care for eligible patients based on clinical guidelines.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the expansion of its care pathway intelligence platform, Tempus Next, into breast cancer. Since its launch in 2024, Tempus Next has screened thousands of patients across its network of provider sites, helping close critical care gaps for patients with lung cancer. Now, the platform will support five different biomarker testing gaps specific to breast cancer with the goal of helping physicians deliver guideline-directed medical care to eligible patients.

Tempus Next supports physicians administering guideline-based care by surfacing care gaps and identifying patients who may benefit from these guideline-based suggestions. The platform integrates multimodal data available in the patient’s electronic medical record (EMR) with up-to-date clinical guidelines to support providers in delivering guideline-based care. As with lung cancer, clinical guidelines around breast cancer are continually evolving, and Tempus is working to help providers keep pace, starting at Mercy, which has already integrated Tempus Next for both breast and lung cancer into its EMR system to support patient care. Mercy has over 1,000 physician practice locations and outpatient facilities, more than 5,000 physicians and advanced practitioners serving patients across Arkansas, Illinois, Kansas, Missouri and Oklahoma.

“Staying current with rapidly evolving clinical guidelines—especially regarding biomarker testing like ESR1 mutations in metastatic breast cancer—remains a challenge for healthcare providers everywhere,” Dr. Jay Carlson, DO, Medical Director of Oncology and Clinical Chair of Mercy Research. “Tools like Tempus Next support our team in identifying patients who may benefit from guideline-recommended testing, helping us deliver truly personalized cancer care.”

“Keeping up with the complex and rapidly evolving clinical guidelines is a nearly impossible task for physicians, especially those in the community setting that are serving so many patients a day,” said Chris Scotto DiVetta, Senior Vice President of AI Applications at Tempus. “We believe it is critical to partner with these providers, such as Mercy, to meet them where they are and design custom integrations that make it easier for their team to deliver optimized care.”

The development of Tempus Next, including its breast cancer module, was funded by Tempus and one or more life sciences company sponsors.

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the expected outcomes and benefits of Tempus Next and its capabilities for customers. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on February 24, 2025, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250630158423/en/